0.31
-0.0098(-3.04%)
Currency In USD
| Previous Close | 0.32 |
| Open | 0.31 |
| Day High | 0.33 |
| Day Low | 0.3 |
| 52-Week High | 4.71 |
| 52-Week Low | 0.25 |
| Volume | 4.09M |
| Average Volume | 1.86M |
| Market Cap | 4.41M |
| PE | -0.06 |
| EPS | -4.99 |
| Moving Average 50 Days | 0.84 |
| Moving Average 200 Days | 1.63 |
| Change | -0.01 |
If you invested $1000 in Moleculin Biotech, Inc. (MBRX) since IPO date, it would be worth $0.43 as of June 28, 2025 at a share price of $0.312. Whereas If you bought $1000 worth of Moleculin Biotech, Inc. (MBRX) shares 5 years ago, it would be worth $3.5 as of June 28, 2025 at a share price of $0.312.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Moleculin Announces $5.9 Million Public Offering
GlobeNewswire Inc.
Jun 20, 2025 1:20 PM GMT
HOUSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today annou
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML
GlobeNewswire Inc.
Jun 18, 2025 11:30 AM GMT
Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer FDA recommends inclusion of patients as young as 6 months – younger than Moleculin had proposed – to be allowed in the pedi
Moleculin Participates in Virtual Investor “What This Means” Segment
GlobeNewswire Inc.
Jun 11, 2025 1:15 PM GMT
Globally recognized Oncology Key Opinion Leader, Brian Andrew Van Tine, MD, PhD, discusses the positive topline results from the U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) Wat